The human immune system is a extremely evolved, complex, multi-component system which protects the organic structure and it ‘s variety meats from the harmful effects of occupying pathogens. It is orchestrated by 9 types of extremely adapted leucocytes. The enlisting of leucocytes to the site of infection, and to antigen present in secondary lymphoid tissue, is an indispensable mechanism in organizing the immune response against pathogens. This mechanism is controlled by a household of chemotactic cytokine proteins called chemokines secreted by septic host cells. Chemokine can adhere to receptors on specific leucocytes to trip them, and/or interact with GAG proteins on endothelial cells and in the extracellular matrix to put up a hepatatic gradient to steer leukocyte migration to the sites of infection/to lymphoid tissue 17. There are four subtypes of chemokines, based on the agreement of their terminal cysteine residues: C, CC, CXC and CX3C23.

Some pathogens have evolved to hedge, mimic or commandeer the host immune system. For illustration certain big two-base hit stranded DNA viruses, such as poxviruses and herpes viruses, are able to modify the normal operation of chemokine to ease viral pathogenesis. This essay will concentrate on the mechanism of action of the poxvirus vaccina virus ( VV ) A41 cistron merchandise and human herpes virus 6 ( HHV-6 ) cistron merchandise U83 in CC chemokine corruption and viral airing.

The Vaccinia Virus

The beginnings of the vaccina virus are unknown. Suggestions include that it is merchandise of familial recombination, an hereditary relation of the smallpox virus, or the leftovers of a now nonextant virus 27. This big two-base hit stranded DNA virus is an archetypical member of the poxvirus household, which are noted to retroflex their Deoxyribonucleic acid in the cytol instead than in the karyon. Its genome contains around 200 cistrons, merely half of which are involved in viral reproduction. The other half are thought to be involved in heightening viral virulency and immune evasion7, 9. The vaccina virus was brought to fame as the unrecorded vaccinum used to eliminate variola, caused by the smallpox virus. Its infection is typically symptomless, or sometimes associated with a mild roseola and febrility. However, in immunosuppressed patients it can do serious complications9.

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!

order now


The A41 cistron is expressed early and late during vaccinia infection and encodes for a glycoprotein which is so secreted by the septic cell. This A41 glycoprotein binds to host CC chemokines, such as CCL21, CCL25 and CCL28. Although A41 does non forestall the chemokines from adhering to effecter receptors, it prevents their interaction with GAG proteins. Chemokine-GAG interaction plays an indispensable function in chemotaxis of leucocytes to sites of infection/to secondary lymphoid tissue by easing the formation of solid stage heptotactic gradients which guide cell migration12, 16, 17, 7. A41 acts to interrupt the enlisting of leucocytes to sites of infection and therefore increases the vaccina viruses opportunities of hedging the immune system and efficaciously circulating 12.

The function of the A41 chemokine adhering glycoprotein has at least two possible clinical deductions. Firstly it could be developed as a curative agent in chemokine related diseases, such as ague and chronic inflammatory diseases, where the inflow of migrating leucocytes in response to chemokine gradients do redness induced tissue harm to the host. A41 could potentially adhere to the overly produced chemokines and forestall the chemotaxis of leucocytes, and therefore prevent tissue harm.

The 2nd possible clinical deduction of A41 is in the vaccina viruse function as a vaccinum. Vaccinia was used to inoculate people once more smallpox. While the run eradicated variola, the vaccinum had a hapless safety record9. The vaccinum late became of involvement once more, because it was feared little syphilis may be used as a biological arm, and inoculation was restated once more in high hazard groups such as the US ground forces 18. Because of this, safer vaccinums are being developed. Research has found that vaccina virus which have had the A41 cistron deleted enhanced viral immunogenicity and produced a more efficacious vaccinum in murine theoretical accounts 9. A41 cistron omission may hence be the following coevals of vaccinums against the possible biological warfare menace of variola.

Human Herpes Virus – 6 ( HHV-6 ) .

There are 8 known members of the human herpes virus household, which are divided into 3 subfamilies ; alpha, beta and gamma. They are all noted for their ability to stay latent in the host after the primary infection. HHV-6 portions the beta herpes virus subfamily with HHV-7. Three cistrons ( U22, U83, U94 ) are specific to HHV-6 and absent from HHV-7 21

HHV-6 is a omnipresent virus thought to infect more than 95 % of the population over 2 old ages old 20. Primary infection most commonly occurs in babies and marks CD4+ T assistant cells This can be symptomless but is frequently associated with feverish unwellness, and less normally exanthem subitum ( a sudden roseola ) , seizures, and encephalitis 22. Following this initial infection, HHV-6 is thought to set up latency in a figure of cell types such as monocytes/macrophages, myeloid and bone marrow progenitors4, 20, 22, 23 and remains in the host for their whole life-time 20. It is hypothosised that latently infected primogenitor cells pass on latent virus through distinction of BMPC to blood cells of different line of descent 4.The latent virus can so reactivate at a ulterior clip, normally in maturity. This reactivation is normally symptomless in healthy people ; nevertheless serious unwellness can happen when HHV-6 reactivates in patients with suppressed immune responses, such as transplant receivers who immune systems are intentionally suppressed to forestall organ rejection or AID suffers 3. In the immunosuppressed this can ensue in a broad scope of pathologies, including bone marrow suppression, pneumonitis, phrenitis, encephalopathy, multiple induration ( MS ) hepatitis, febrility, transplanted organ complication/rejection and decease 11.

Because HHV-6 is lymphotrophic – peculiarly for CD4+ T cells which are of import in activation of humoural and cell mediated antigen specific immune responses 2, 3, 4, 21 – there are deductions that HHV-6 may do immune suppression in a similar mode to the AIDs causation HIV virus, though farther research is needed. 4. HHV-6 is besides extremely neurotrophic and linked to several neuroinflammatory diseases 21.

HHV-6 has evolved to encode for the production of 2 chemokine receptors ( U12 and U51 ) , which bind endogenous host chemokines to trip cellular reproduction to advance viral airing, and one viral chemokine, U83, which interacts with host receptors 2. Two strains of HHV-6 virus have been identified: HHV-A and B. U83 is the lone HHV-6 hypervariable cistron identified, and so is thought to be extremely important in the different between their pathologies 3. HHV-6B is significantly more prevailing discrepancy in the USA, Europe and Japan, though in Africa the two discrepancies are thought to be every bit common 3. Due to variant B prevalence it is thought to do the normally seen feverish unwellness, where as discrepancy A is proposed to be linked to more terrible pathology 6, 26. This may be due to the ability of HHV-6A to non merely infect CD4+ T assistant cells, but besides other cytotoxic effecter cells such as CD8+ cytotoxic T cells, NK and gamma delta T cells which involved in antiviral defense mechanism. This is thought to help HHV-6A ‘s equivocation of the immune system 4.

HHV-6 enter cells via an interaction with the human glycoprotein CD46 receptor nowadays on all nucleated cells – though there is some grounds that certain strains may come in through a different receptor e.g the HST HHV-6B strain and may farther explicate the differences in cellular tropism and pathology shown between different strains. This HHV-6-CD46 interaction is besides associated with a figure of immunomodulator effects, including the deregulating of the complement system – perchance doing complement induced lymphoid tissue harm 4, 21.

While both discrepancies secrete a CC chemokine encoded by U83 cistron, little differences in the cistron between the discrepancies result in structural and functional differences between the produced glycoprotein chemokines. The chemokine produced by HHV-6A ‘s cistron U83A is called pU83A and by HHV-6B ‘s cistron U83B is called pU83B. 20

HHV-6B and U38B

U83B chemokine has been found to be an effectual agonist of the CCR2 receptor, despite holding a comparatively low affinity interaction 3, 20. CCR2 are normally found on monocytes 6, and U83B has been found chemoattract such CCR2 bearing cells every bit effectively as the endogenous CCR2 ligand chemokine CCL2 20. Expression of the U83B cistron is thought to happen tardily in infection, after viral DNA reproduction, and is therefore thought to play an of import function in airing of the virus. Infected cells, chiefly CD4+ T assistant cells, showing the viral U83B secrete the encoded chemokine merchandise, which mimics the effects of CCL2: it binds to CCR2 to bring on cellular Ca immobilization and initiate chemotaxis of the cell to the site of viral infection, enabling viral airing to migrating monocytes 1. It is thought that every bit good as being a mechanism to distribute the disease, HHV-6B so established latent infection in CCR2 bearing monocytes 1, 20.

It has been suggest that latent infection of CCR2 bearing cells by HHV-6 may play a function in the pathogenesis of the neuroinflammatory disease multiple induration ( MS ) during viral reactivation. During MS it is hypothesised that microglial cells of HHV-6B septic monocyte linearage secrete U83B upon viral reactivation, and do the migration of CCR2 bearing leucocytes across the bloodbrain barrier and do the inflammatory nervous harm, such as demylination, associated with MS 20. Further research is needed, but this would connote that U83B is a possible curative mark for the intervention of MS 23.

Another possible curative application of U83B is disposal at the sites of tumors. The attractive force of tumour mortification factor releasing monocytes to the cancerous country could help the programmed cell death of tumor cell and cut down the demand for surgical remotion 23.

HHV-6 and U83A

Two subtypes of U83A like CC chemokine exist, a spliced fluctuation with a N terminal shortness ( U83A-N ) and the full length signifier ( U83A ) . U83A-N is expressed in the immediate-early stage of HHV-6A infection ; it inhibits the chemotaxis of leucocytes such as monocytes, dendritic and T cells, through hostility of certain CC receptors, such as CCR1, CCR4, CCR6, CCR8 and peculiarly CCR5 6.This mechanism is thought to significantly cut down the host immune response to endogenously produced chemokines by competitively adhering to their mark receptors before the virus has even complete reproduction, and hence increase the opportunities of viral proliferation and airing 3.

The full length version of the U83A, expressed in the latent stage of HHV-6 A infection is besides thought to competitively barricade endogenous chemokines, and more effectively than the abbreviated U83A-N signifier 2. However, U83A has farther go-between effects. Unlike U83A-N, every bit good as competitively adhering to CCR1, CCR4, CCR5, CCR6 and CCR8 CC chemokine receptors to barricade endogenous chemokine binding, it can besides move as an agonist on the receptors, bring oning G protein activation, receptor internalization, Ca mobilization and chemotaxis of leucocytes bearing these receptor types. Although al the afore mentioned CCR receptors can interact with U83A, CCR5 is of peculiar significance as U83A binds to this receptor with a higher affinity than any know chemokine-receptor interaction 6. Endogenous chemokines normally induce receptor internalization via a rapid clathrin mediated pathway, taking to chemotaxis of leucocytes to the site of infection. However U83A stimulated receptors are internalised via a delayed caveolin tract. Thus it chemoattracts leukocytes to circulate to, but by detaining the signalling tract, it attracts not activated CCR1, CCR4, CCR6, CCR8 and peculiarly CCR5 bearing cells 2. It is besides likely that the discriminatory binding of U83A to receptors means that there are increased concentrations of endogenous chemokine, which may trip their consumption by regulator scavenger receptors such as DARC, farther cut downing their ability to pull activated leucocytes to the site of infection 2.

Of the 3 chemokines reviewed, U83A presently has the widest range for curative usage and adaptation, which will now be discussed.


As with U83B, disposal of U83A at tumor sites would promote the inflow of leucocytes and increase the antigenicity and violent death of tumor cells, which tend to hold low immunogenic belongingss. Besides an endogenoud ligand of CCR6 called CCL20 has been reported to suppress leukemia of myeloid primogenitor. As U83A is besides a ligand of CCR6, there is a possible curative usage for U83A as a anti-cancer drug 3.


Given the broad scope of receptors and immune cells U83A can trip and chemoattract, there is the possible for its administer with vaccinums, as it could pull immune cells to the vaccinum and heighten the immune response, therefore go forthing the patient with improved immunity3. This may be peculiarly true for usage with skin mucosal-directed vaccinums, as pU83A induced CCR4, CCR6, and CCR8 bearing cells have peculiar tegument homing abilities, and pU83A besides stimulates the inflammatory receptors CCR1 and 5. Thus pU83A ‘s immunostimulatory abilities could be manipulated to better the efficiency of vaccinations6.

Inflammatory and autoimmune diseases

Chemokine over production has been discovered to play an of import pathophysiological function in several inflammatory diseases and autoimmune disease such as arthritic arthritis and coronary artery disease. The counter belongingss of pU83A-N on chemokine receptors of leucocytes involved in inflammatory pathogenesis have deduction as possible anti-inflammatory drugs for such diseases 23.


There is experimental grounds that U83A could hold a possible function in cut downing the pathogenesis of HIV-1 strains which use CCR5 as a co-receptor. Data has already highlighted CCR5 as a curative mark for HIV suppression as omission mutants seen in the population confabulate some opposition to HIV and in some HIV infected patients CCR5 antibodies are produced which cause down ordinance of CCR5 look and suppression of HIV. Catusse et al 2007 found that HIV-1 infection of human PBMC was inhibited by 95 % in the presence of pU83A-N due to direct competition of CCR5 binding. For grounds non stated this peculiar experiment was non performed with the full length pU83A, though due to the greater affinity pU83A has with CCR5 compared to pU83A-N, it could be expected that the full length chemokine would hold an even greater inhibitor consequence. This combined with its immunostimulating abilities mark U83A for farther research as a HIV-1 intervention 6.

Evidence that suggest that HHV-6 interacts with HIV in the concerted depletion of CD4+ T assistant cells, speed uping patterned advance to AIDs would look to belie the above evidence4. However given that lone suppression of HIV-1 strains which use CCR5 as a co-receptor and merely by HHV-6A discolorations was shown, and so more elaborate research into non CCR5 co-receptor strains of HIV-1 and HHV-6 co-depletion of CD4+ T assistant cells is needed. Further research may take to the development of a HHV-6 vaccinum used as a combination therapy for HIV intervention to detain the patterned advance to AIDs.

Neuroinflammatory diseases

U83A is has besides been linked to MS and other neuroinflammatory diseases. There are several theories of the proposed, one already reference sing U83B bring oning migration of macrophages/monocytes to nervous tissue which may do redness and demylination 23. A similar theory proposes that U83A induces macrophage migration to nervous tissue through activation of CCR1, 5 and 8 receptors on the leucocytes, which cause nervous redness and demylination. Supporting grounds shows that correspondent HHV-7 virus, which portions many cistrons with HHV-6 but notably non the U83 cistron, is non linked with MS. Clearly more research is needed, but experiments investigated agonistic U83A as a curative mark and counter U83A-N as a possible curative drug may give the following coevals of MS intervention 3.


  1. P. Zou et Al. 1999. Human herpesvirus 6 unfastened reading frame U83 encoding a functional chemokine. Journal of virology. 73:5926-5933.
  2. J. Catusse, D.J. Clark, and U.A. Gompels. 2009. CCR5 signalling, but non DARC or D6 regulative, chemokine receptors are targeted by herpesvrius U83A chemokine which delays receptor internalization via recreation to a caveolin-linked tract. Journal of Inflammation. 6:22.
  3. D. R. Dewin, J. Catusse and U.A. Gompels. 2006. Designation and word picture of U83A viral chemokine, a wide and potents & A ; szlig ; -chemokine agonist for human CCRs with alone selectivity and inhibibition by spliced isoform. The diary of Immunology. 176:544-556.
  4. P. Lusso. 2006. HHV-6 and the immune system: Mechanisms of immunomodulation. Journal of Clinical Viriology. Supplement 1: S4-10.
  5. A. Alcami. 2007. New penetrations into the corruption of the chemokine system by poxviruses. European diary of Immunology. 37:880-883.
  6. J. Catusse, C.M. Parry, D.R. Dewin and U.A. 2007. Gompels. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leaukocytes chemotaxis and receptor internalisation. Blood. 109:3633-3639.
  7. M.W. Bahar. 2008. Structure and map of A41, a vaccina Virus chemokine adhering protein. PLoS Pathogens. 4:55-68.
  8. A. Alcami and M. Saraiva. 2009. Transition of the chemokine system by pathogens. Pathogen-derived Immunomodulatory Molecules.
  9. R.H. Clark et Al 2006. Omission of cistron A41L enhances vaccinia virus immunogenicity and vaccinum efficaciousness. Journal of Virology. 67:29-38.
  10. A. Ng et Al. 2001. The vaccina virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulency. Journal of Virology. 82:2095-2105.
  11. G. Campadelli-Fiume, P. Mirandola, and L.Menotti. Human Herpesvirus 6: An Emerging Pathogen. Emerging Infection Diseases. Review 01/07/99. Viewed 14/11/09. Hypertext transfer protocol: //
  12. Z. Johnson a, A.E. Proudfoot B and T.M. Handel. 2005. Interaction of chemokines and glycosaminoglycans: A new turn in the ordinance of chemokine map with chances for curative intercession. Cytokine & A ; Growth Factor Reviews. 16: 625-636
  13. W. Weninger and U.H. Andrian. 2003. Chemokine ordinance of naif T cell traffic in wellness and disease. Seminars in Immunology. 15:257-270
  14. Scott N. Mueller et Al. Regulation of Homeostatic Chemokine Expression and Cell Trafficking During Immune Responses. Science. 317, 670 ( 2007 ) ;
  15. M.B. Ruiz-Arguello et Al. 2008. An Ectromelia virus protein that interacts with chemokines through their glycoaminoglycan binding sphere. Journal of Virology. 82:917-926.
  16. B.T. Seet and G. McFadden. 2002. Viral chemokine-binding proteins. Journal of Leukocyte Biology. 72:24- 33.
  17. C. Vanpouille et Al. 2007. Interactions between HIV virus type 1 and vaccinia virus in human lymphoid tissue ex vivo. Journal of Virology 81:12458-12464.
  18. M. Mayne. 2001. Gene Expression Profile of Herpesvirus-Infected T Cells Obtained Using Immunomicroarrays: Initiation of Proinflammatory Mechanisms. Journal of Virology. 75: 11641-11650.
  19. H.R.Luttichau et Al. 2003. A extremely selective CCR2 chemokine agonist encoded by HHV6. The Journal of Biological Chemistry. 278:10928-10933.
  20. L. De Bolle, L. Naesens and E De Clereq. 2005. Update on Human Herpesvirus 6 Biology, clinical characteristics and therapy. Clinical Microbiology Reviews. 18:217-245.
  21. R. Sjahril et Al. 2009. Relationship between U83 cistron fluctuation in human herpes 6 and secernment of the U83 cistron merchandise. Archivess of Virology. 154:273-283
  22. M.N. Ajuebor, M.G. Swain and M. Perretti. Chemokines as fresh curative marks in inflammatory diseases. Biochemical Pharmacology. 63:1191-1196.
Written by

I'm Colleen!

Would you like to get a custom essay? How about receiving a customized one?

Check it out